SCHEMBL6680077

SCHEMBL6680077

CN1C(=O)C(Cc2ccc(F)c(F)c2)C(=O)c2cc(C(=O)O)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.40
NR1H3 Q13133 2/20 0.40
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
HTR7 P34969 1/20 0.38
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
PARK7 Q99497 1/20 0.37
POLB P06746 2/20 0.35
ALOX15 P16050 1/20 0.35
CCKAR P32238 4/20 0.35
CCKBR P32239 4/20 0.35
TBXA2R P21731 1/20 0.35
PTGER4 P35408 1/20 0.35
PTGER3 P43115 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6685279 0.90 NR1H2 (0.38) NR1H2NR1H3KDM4EALDH1A1HPGD
SCHEMBL6681227 0.90 PRKAG1 (0.39) NR1H2NR1H3KDM4EALDH1A1HPGD
SCHEMBL6664689 0.90 PSEN1 (0.43) NR1H2NR1H3PSEN1PSEN2APH1B
Niacinamide SCHEMBL6669309 0.87 PSEN1 (0.41) NR1H2NR1H3PSEN1PSEN2APH1B
SCHEMBL6664550 0.86 ROCK2 (0.43) NR1H2NR1H3HTR7KDM4EALDH1A1
SCHEMBL6664500 0.86 NR1H2 (0.41) NR1H2NR1H3HTR7KDM4EALDH1A1
SCHEMBL6678968 0.85 NR1H2 (0.49) NR1H2NR1H3KDM4EALDH1A1HPGD
SCHEMBL6662847 0.84 TSHR (0.41) NR1H2NR1H3KDM4EALDH1A1HPGD
SCHEMBL6681355 0.84 HTR7 (0.49) HTR7ALDH1A1POLB
SCHEMBL6680821 0.83 ALDH1A1 (0.41) NR1H2NR1H3KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors HICKS JAMES LESTER (US) 2004-03-04 US disclosed
WO-2004014388-A1 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors MMP13, MMP26, MMP9 NR1H2 374/4885NR1H3 597/4885PSEN1 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.